MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
May 31, 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
Download
May 16, 2018
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Download
May 14, 2018
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
Download
May 08, 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Download
April 04, 2018
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Download
March 27, 2018
Daiichi Sankyo, Inc. and the Crohn’s & Colitis Foundation Launch Get Iron Informed
Download
March 27, 2018
Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Download
March 07, 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
Download
February 28, 2018
Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
Download